Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel in Bone Metastatic Castration-Resistant Prostate Cancer
NCT02512458Phase 2Completed
- Sponsor
- HeCOG
- Start
- Oct 2015
- Primary completion
- Dec 2019
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by HeCOG. Started Oct 2015; status: completed.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02512458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02512458.